Flotek Industries, Inc. (FTK) Earnings Call Transcript & Summary

March 6, 2020

New York Stock Exchange US Materials Chemicals earnings 33 min

Earnings Call Speaker Segments

Danielle Allen

executive
#1

Good morning, and thank you all. We're glad you could join us. On the line with me today are John Gibson, our Chairman, Chief Executive Officer and President; Ryan Ezell, Senior Vice President of Operations; Nick Bigney, Senior Vice President, General Counsel and Corporate Secretary; and Elizabeth Wilkinson, our Chief Financial Officer. To kick off today's call, we'll go through prepared remarks about the business and our results for the quarter and the full year. After that, we'll take whatever questions you have. Yesterday, our earnings announcement for the fourth quarter and full year 2019 came out, and you can find it on our website. This call is being webcast, and a replay, together with our updated corporate presentation, will be posted on our website as well. Please keep in mind that anything we say today about projections or what we expect for future events counts as forward-looking statements. Such statements carry a number of risks and uncertainties, many outside our control; these risks and uncertainties could make actual events turn out materially different from what we currently expect; listeners should look over our earnings release and the risk factors covered in our SEC filings. Additionally, please see the reconciliations in our earnings press release, since management might talk about non-GAAP metrics on this call. With all that said, I'll pass things to John.

John Gibson

executive
#2

Thank you, Danielle, and we're glad all of you could be with us on today's call. Before I move into my remarks, since this subject matters so much, I'll hand things back over to Danielle so she can bring everybody up to speed on the procedure Flotek has established regarding the coronavirus. Danielle?

Danielle Allen

executive
#3

Thanks. Like John mentioned, we understand how crucial it is to prepare for possible situations and expected effects tied to coronavirus. That is why a task force has been put together, made up of leaders from throughout the company, with additional support from feedback given by important suppliers and customers. Using direction from the CDC, the WHO local health organizations, and OSHA, this task force has created action plans meant to tackle associated risks, and we keep watching this highly fluid situation. Over to you, John.

John Gibson

executive
#4

Thank you, Danielle. As she mentioned, we're spearheading a significant initiative at Flotek to prioritize people, and that covers both our customers and our suppliers. Given how seriously we approach ESG and how much the well-being of our employees and suppliers matters to us, it's wonderful to be here, and I'm extremely appreciative of the warm reception I've gotten from customers, shareholders, supplier partners, employees, and the board. I feel humbled and grateful that all our stakeholders took the time to share their views with me regarding Flotek's strengths and its opportunities. Because this is my inaugural call, I'd like to tell you what to expect from both me and the team during our quarterly calls. On this initial call, I want you to become a bit more familiar with who I am, where I come from, and the path forward as I see it. Going ahead, you'll probably be hearing less from me and more from the company's leadership team, and we're going to begin introducing them to you right now. What you won't be hearing from me are commitments regarding what I'm hoping to deliver down the road. Let me be clear: I'm relentlessly committed to execution, and my intention is to concentrate on what we've already achieved together as a team rather than making pledges about things we haven't yet completed. Now, from my conversations with our shareholders, a question that comes up most often is: why did you join Flotek? I'd like to offer my perspective to those I haven't yet had the opportunity to meet. To start, I'll tell you a bit about where I come from. Over a span of more than 25 years, my career has centered on finding and bringing to market distinctive and disruptive technologies within oil and gas. I joined Flotek from Tudor, Pickering, Holt, where I headed the energy technology team — which concentrates on emerging oil and gas technologies — and I still serve as a senior advisor to it. So, an excellent group of people there at TPH. Before my time at TPH, I served as President and CEO of Tervita, a prominent environmental and oilfield services firm headquartered in Canada. Before that, I was President and CEO of Paradigm Geophysical, Landmark Graphics, and also served as President within Haliburton's Energy Service Group. The first 12 years of my career involved a range of positions at Gulf Chevron in exploration and production research. So, I've been on the producing side, the technology side, the oilfield service side, and the environmental side. I've witnessed our industry in its entirety, and I'm thrilled to be working in chemistry, specifically specialty chemistry; so, why did I choose to come to Flotek? Well, I felt that the skills I've built throughout my career align rather well with Flotek's circumstances. I've built a solid history of tackling tough problems and creating successful, substantial companies — often starting from scratch or fixing a struggling operation — and every time, that calls for crafting a shared vision, the strategies to back it up, and then disciplined follow-through. On top of that, I have a financial stake in Flotek doing well. Before I came aboard, I collaborated closely with the board to put a compensation package in place that leans heavily on equity. Because of that, my interests line up with shareholders who want to see meaningful gains in our stock price going forward. I'd also point out that the way my pay is set up, I won't receive any bonus for 2020 unless we hit at least breakeven adjusted EBITDA for the entire year. Ultimately, that translates to roughly a $35 million year-over-year gain in adjusted EBITDA — so it's pretty clear what's driving me in 2020. When I came to Flotek, my top priority was finding further chances to cut costs. Collaborating closely, we've set out on a path to trim every expense so we can speed up our return to profitability in 2020. One clear illustration is the recent change to our terpene supply agreement with Florida Chemical Company that we flagged in our latest 8-K. I'll let Ryan walk through the main terms of that revised deal now, but the key point is that the new and amended contract's provisions will substantially boost our cost position and cash flow. Ryan?

Ryan Ezell

executive
#5

Thanks, John, and good morning, everyone. We're happy about the changes made to the terpene supply agreement currently in place. This revised contract marks a major step forward in Flotek's strategic relationship with Florida Chemical Company, as well as in our capacity to handle inventory and related costs. Allow me to walk through the main terms of the prior agreement and what followed from them. Under the original deal, we were obligated to buy roughly double the terpene value needed to serve our existing business. That left us with surplus inventory and storage expenses. On top of that, the effective price under that agreement sat far above what the market offered. Together with FCC, we set out to bring the agreement in line with our present business. To get there, we settled on cutting the amount of terpene we had to buy from FCC by about three-quarters for 2020, and by roughly 50% in 2021, 2022 and 2023, and we also settled on an all-in fixed price per pound of terpene for 2020 that sits 45% under the original agreement's price. To put the amended terms and conditions into force, Flotek paid FCC a one-time sum of $15.8 million. Counting that payment, our commitment drops to under 50% of the original contract when measured against current market pricing; beyond that, the volume reduction price we settled on for terpene purchases under the amended contract in 2020 by itself ought to largely offset the one-time $15.8 million cash payment to FCC. I'd also like to point out that across 2021, 2022 and 2023, the roughly 50% volume cut negotiated for each of those years ought to shrink our cash commitments in proportion. The bottom line is that we're now set up to compete more effectively in the market when it comes to procurement and our customized chemical solutions portfolios, and that creates room to chase new routes to market. Since I came to Flotek at the end of August, we've been unrelenting in hunting for ways to bring operational cost down and build positive synergies. Value stream mapping and continuous improvement work have delivered millions of dollars in annualized cost savings across strategic sourcing, logistics, field operations and facilities management. The amended terpene agreement is one more step forward and reflects our dedication to reaching positive profitability. With that, I'll hand things back to John.

John Gibson

executive
#6

Thanks, Ryan. By changing the terpene agreement's terms, we're obviously in a stronger spot to deliver better financial results in 2020. There's more work ahead, though. Several opportunities have come to light that would let us streamline our office footprint while keeping our market presence intact. Our plan is to leave the current headquarters plus 2 satellite offices during the next quarter. Over the remaining life of the leases, that ought to bring expenses down by millions of dollars. While we're on the subject of that relocation, I've told our staff we'll get it done fast — even if that means putting concrete blocks across the few doorways from lows to pull off the move as speedily as possible. Beyond that, we think there's room to strengthen risk mitigation and also cut legal cost. To walk through what we're seeing on the legal front, I'll pass things to Nick, our new General Counsel and a terrific addition to the team. Nick?

Nick Bigney

executive
#7

Thank you, John, and hello everyone. It's a pleasure to be part of this team. Even though my time with the company has been brief, I'm eager about the possibilities ahead to strengthen how Flotek handles legal matters; our attention is on corporate governance, compliance efforts, and lowering the legal risks we face, and specifically, we're aiming to improve every one of our board engagements, our international trade compliance, our export controls, HR-related policies and other similar company issues; we're confident that dedicating resources to these areas will cut down our continuing legal exposure, above all within our international operations. We're also pushing to decrease what we pay to outside legal providers. Flotek's legal costs have traditionally run high, and there's room for a meaningful reduction. As an example, we plan to take advantage of smaller reporting company rules for our SEC filings, which makes that process simpler. On top of that, we're moving additional work in-house and turning to outside advisors only where it's needed and makes financial sense. Although we're still in the process of pinpointing every opportunity, our aim is to lower our legal expenditures to a level at or below what a company of our size would be expected to spend. I'm eager to collaborate with the rest of the team to create a positive impact moving forward. John?

John Gibson

executive
#8

Thank you, Nick. Having Nick join us is genuinely a pleasure. When I look at where things stand today for Flotek's offerings, one thing is obvious: we have to expand our share of the market by showing how and why our chemistry outperforms what competitors offer, and by delivering measurable value to our customers in an environment where cost control matters enormously. A great deal of my attention has also gone toward assessing our sales operation — specifically, how we might connect more effectively with both existing and potential clients. There is broad agreement — pardon me, I misspoke; I wish it weren't so — that 2020 will bring considerably more softening in the U.S. onshore oil and gas market. Even so, we think greater uptake of specialty chemicals has the potential to more than make up for reduced drilling and completions activity. Of the wells currently being completed, hardly any actually rely on specialty chemicals, so even a drastic drop in drilling volume and activity shouldn't hinder our capacity to deliver results on the wells that are still being completed. Our primary sales objective is a market growth strategy built on three things: boosting returns for existing customers, reestablishing ties with former customers, and finding new customers who stand to gain from our chemistry solutions. On top of that, we are sharpening our emphasis on the total cost of recovery per barrel of oil equivalent instead of merely the upfront purchase price, and we are reinforcing the publicly documented proof that advanced C&F products work — that they meaningfully affect oil and gas recovery and operator profitability. Since I came to the company in early January, I've devoted time alongside Mark Lewis, our Senior Vice President of Global Business Development and Sales, and members of his teams, to reviewing our market strategy and related initiatives, and I've joined Mark on a number of sales calls. Our direct sales channel concentrates on customers where we see a strong likelihood of improving their returns through technology — that's something we intend to keep doing; we aim our efforts at customers pursuing the greatest return on capital rather than the smallest initial purchase cost per activity. We plan to preserve and build upon our knowledge and evidence regarding chemistry's beneficial effect on well production, completion designs and spacing models. So this year, our emphasis will be on analytics, inside the company and outside it, which means in many instances working alongside particular customers, anonymously, who are prepared to provide the necessary data so we can publicly confirm the better long-term profitability of wells treated with Flotek's proprietary chemistry — it's extremely typical these days for businesses to supply their data anonymously, letting us leverage big data analytics to grasp the full picture of trends and enhanced outcomes; we also anticipate bringing in outside specialists in digital fluid flow modeling to deliver production forecasts for wells treated and untreated, which we'll use in conversations with customers regarding our products. Beyond that, we'll keep funding R&D so our products and services stay differentiated, and in our view that differentiation will decide who wins and who loses in this market. Last, rather than having a formal strategic capital committee within the company — the formal strategic capital committee — the company will keep assessing alternatives alongside the Board of Directors for how to deploy the cash we hold. What we're currently evaluating for additional capital deployment covers pursuing growth opportunities that lessen our reliance on rig count, delivering new product lines that generate a larger backlog and/or revenue that recurs annually, preserving how our offering stands apart from rivals, boosting our ability to deliver digital transformation of chemistry, leveraging my experience at Landmark, at Paradigm, and TPH, and reinforcing our market share for the product launch we have underway now. The bottom line: we think our cash position, our public equity, our North American presence, the fact that we carry no debt, our ongoing emphasis on cutting costs, and our dedication to ESG all make us highly attractive. With no IPO market to speak of, we've ended up with a portfolio of many opportunities looking for liquidity. We're vetting those opportunities in order to choose the ones that deliver the most long-term shareholder value. With that, I'll hand things over to Elizabeth to go over our financial results — though it's fortunate I've already handed it over. I'm handing it to Elizabeth. She'll take us through the financial results. Elizabeth?

Elizabeth Wilkinson

executive
#9

Thanks, John. Just like we've seen in recent quarters, the financial tables included in our press release show our CICT segment's operations as a discontinued operation across all periods. So today, my discussion will center on quarterly results from our continuing operations, which takes in our energy business along with our supporting research and innovation and corporate functions. Turning to our financial results, revenue came in at $19.5 million for the fourth quarter, down from $21.9 million in the third quarter. ECT operating expenses totaled $42.6 million in the fourth quarter, compared with $23.7 million in the third quarter. During Q4, we took a $15.8 million hit from losses on purchase commitments connected to the 2019 terpene supply agreement, and we also booked an extra $4.4 million reserve tied specifically to the terpene inventory balance we held as of December 31, 2019. Because of the supply chain and operational efficiency improvements made during 2019, as well as the amendment we negotiated to the terpene contract, we now have the ability to actively adjust inventory down to reduced levels moving forward. Corporate G&A climbed to $9 million in Q4, up from $5.7 million in Q3, largely because of $3.7 million in severance recorded during the quarter, mostly associated with our former CEO's departure. On the R&I side, expenses came in at $2.2 million, down from $2.3 million during the prior quarter. Looking ahead from here, our expectation is that corporate G&A will run at an average under $5 million each quarter, while R&I should average roughly $2 million per quarter. For the fourth quarter, we posted a loss from continuing operations of $37.1 million, which works out to $0.64 per diluted share, versus a third-quarter loss of $11.2 million, or $0.19 per diluted share. As noted earlier, the fourth quarter took a substantial hit from the loss on purchase commitments tied to the terpene supply agreement, the extra reserve we booked against the terpene inventory balance at year end, and severance totaling $3.8 million. During Q4, adjusted EBITDA came in at a loss of $8.9 million, versus a loss of $8.1 million in Q3. That shift mostly reflects margin compression driven by reduced revenue. For additional specifics on adjusted EBITDA, you can check the table included in the release. Moving over to the balance sheet: on December 31, cash and equivalents stood at $100.6 million, we carried no debt, and $9.9 million of escrowed funds remained on our balance sheet, representing our estimated claim to what's left in the indemnity escrow tied to selling Florida Chemical to Archer-Daniels-Midland, or ADM. During the fourth quarter, we recorded a $15.8 million loss tied to purchase commitments, along with a $4.4 million reserve against terpene balances as of 12/31. Those charges reflect our view that, as we look ahead to the rest of the term under our 2019 terpene supply agreement, neither the pricing nor the volumes specified in that contract matched what we now intend to do — selling terpenes in a range of formulations as well as in raw form through possible new distribution channels. That allowed us to recognize a loss on the contract commitment as it existed on December 31, 2019, and to set up a reserve against a particular share of the terpene inventory we held on that date. As Ryan mentioned last month, we made a $15.8 million payment to FCC in order to amend the terpene supply agreement. Next, in February 2020, an independent third party that ADM and Flotek brought in together to settle the working capital disagreement between us that arose after closing on the transaction ruled in ADM's favor, granting $4.1 million — the full amount that had been in dispute. Because this is recorded as a subsequent event, that figure, after tax, is reflected as a loss within discontinued operations for Q4 2019. Agreeing with the points John and Ryan raised, in addition to putting ourselves in position to cut inventory substantially moving forward, we have identified further opportunities during the last two months to enhance our cost structure even more. These efforts extend the approximately $30 million in annualized cost savings throughout the business that we put into place during 2019. We can't wait to share more specifics about what we're working on right now when our first quarter numbers come out in two months' time. At this point, we're ready to take your questions. Just so you know, Mark Lewis is with us for the Q&A, along with James Silas, who serves as Senior Vice President of Research and Innovation. Over to you, operator.

Daniel Burke

analyst
#10

Hi good morning everyone.

John Gibson

executive
#11

Good morning, Daniel.

Daniel Burke

analyst
#12

John, when it comes to the top line, I get the upside adoption case you laid out for this year, but you also mentioned possible risk from customer concentration — does that create any difficulties for you folks when you weigh your customer base in 2019 against the activity levels those customers are proposing for 2020? And then, if I may pull this out of you, since we're already fairly far into Q1 ‘20, do you have any views on near-term top line trends here in Q1?

John Gibson

executive
#13

All right. That's a really thoughtful question, Daniel, just give me a moment here. First off, since I came on board, if we frame it as numerator and denominator, most of my first 60 days went to the denominator, trying to identify what we believe could be an estimated $15 million of extra cost in 2020, and that has been where our attention sits. On the numerator, I've put in some time on the revenue side alongside Mark and Q1, and we are indeed working on it — I don't want to provide any guidance there — but on the customer concentration issue, we do have a few large customers who have stayed very loyal and who we're thrilled to serve, and we're growing past that. So both Mark and I are focused on bringing in a wider spectrum of customers. As I've mentioned previously, not many wells — I mean, my suspicion is that a single-digit percentage of completions actually use specialty chemicals. So what we have to solve is ensuring the specialty chemical business for completions as a whole grows, and then we want to capture that market share; so I feel fairly confident about the numerator, but we're going to grow past simply leveraging our chemicals. We also have some infrastructure that we believe will prove quite valuable to us in the coming year. And so we're examining — there's nothing we hold that we won't attempt to generate shareholder value from through revenue; and so I realize the question will arise about when breakeven shows up; and I can say, I don't want to give guidance on that, but take it that I won't receive a bonus until I reach it, and I fully intend to earn a bonus for 2020; so the date when I reach it on a full year basis is TBD. On the revenue side, we had some — plenty of logistical issues that got resolved in ‘19. Credit to Ryan and the team there. And I believe the sales team is truly starting to focus and gel around what the customer value proposition is. And so we're quite excited about that. But give me until the end of Q1 and come back at the end of Q1 and I'll devote the entirety of the call to the revenue side of the equation — that's the better call.

Daniel Burke

analyst
#14

That seems logical to me. As a quick follow-up to get a bit more clarity, John — I believe you mentioned a focus on another $15 million in cost savings for 2020. It may be obvious, but I want to confirm that this would come on top of what you'll save through the new terpene price arrangement. Is that correct?

John Gibson

executive
#15

Yes, that was part of it — I'd say there are sort of three buckets where we've achieved genuinely strong cost savings that I'm able to quantify. First is the terpene agreement. Then there's the drop in outside legal expenses, which comes from bringing Nick on board, along with the office relocations. So that's three, and it doesn't mean we're finished there. It simply means those three are the most significant ones we've pinpointed in the first quarter.

Daniel Burke

analyst
#16

Okay. So that ‘15 in 2020 — that isn’t an exit run-rate, and that’s useful. Fine. Then, maybe one more thing: regarding the cash balance, all of you mentioned growth as the focus for deploying that cash. Could you perhaps — it definitely stands to reason that some interesting or attractive deal opportunities exist out there, but what deal size makes sense for the company? What do you think is the right range of deal size for you all to consider?

John Gibson

executive
#17

Well, that’s another really good question. It seems pretty easy for us to see that by using a mix of cash and equity, we believe we could do deals, given the really low multiples, that could bring in revenues ranging anywhere from, say, $15 million for a higher multiple sector to as much as $200 million in the lower multiple sector. So we are sort of vetting deals that range from at the low end $15 to the high end to a couple of 100 that we think are things we would be able to do.

Daniel Burke

analyst
#18

All right, that's enough from me at this point. I appreciate you taking the time.

Jim Kennedy

analyst
#19

Hello, John. Glad to have you on the team.

John Gibson

executive
#20

Thanks.

Jim Kennedy

analyst
#21

Hi, Elizabeth. Hey, John, this might be one for Mark, but I'm curious — given the brief period you've been there, could you talk a bit about the sales force and go-to-market approach, and how you expect that to develop throughout this year? Things like where the emphasis will be, possibly headcount, and how it might differ from what was done previously — can you address that kind of go-to-market strategy?

John Gibson

executive
#22

I'll start with a quick summary, then hand things over to Mark. Something that happened was the business shifted from being largely indirect to largely direct back in 2019. Looking ahead, we're going to sell product higher where we sell product, and that means adopting a direct channel approach, since we believe that matters for a certain set of customers. We're going to bring back the direct sales channel approach. We believe that's an excellent way to reach a big chunk of the market, especially internationally and in certain respects, and we're working through that. And we're also considering what we'll call quite labeling our products — letting others sell our advanced products under their name. So, if there's any way to sell products, you can assume all of that is fair game for us today, because we're interested in amplifying our sales and we think all of those different methodologies can result in improved sales. I had a chance to make a few calls with Mark; so, Mark, do you want to talk about the direct? I mean, what's your — when you're meeting with customers, what's the real value proposition that you explain to people today?

Mark Lewis

executive
#23

To my mind, the genuine value we bring lies in boosting the rate of return. Many of the clients we serve are plainly operating inside their cash flow, constrained when it comes to CapEx spending, and quite strict about the CapEx dollars they put to work. Because of that, our attention stays squarely on what the customer gets out of it; and several of our flagship technologies — the CnF technology especially — genuinely deliver incremental production across quite a few situations in the marketplace. That's why I'd call our value proposition genuinely, genuinely powerful. On top of that, our sales force is geared toward delivering those client outcomes. Over roughly the past 6 to 9 months, we've retooled and essentially rebuilt the whole sales organization; as a result, we now have a complete roster of sales personnel across the main basins where our focus sits — the Northeast along with Midland, Denver, Dallas, Huston and Oklahoma — and these individuals are highly professional. They're professional salespeople in those roles: chemists, chemical engineers, petroleum engineers, business graduates, every one of them a graduate, all centered on what the client achieves. So our confidence is high, and so is our confidence in our sales staff's capacity to deliver the correct outcome for the customer.

John Gibson

executive
#24

Jim, another item we addressed was that considerable attention went toward shifting our sales channel and bringing in a new one, plus giving those efforts room to prove themselves. From here on out, we simply will not offer any justifications tied to anything at all. Consequently, no matter what comes our way, the outcomes delivered by this company rest on our shoulders. Therefore, I will not bring up our sales channel or debate whether it happens to be fresh or in transition. Growing this company's revenue is a duty we carry, and our attention will stay fixed on accomplishing exactly that; and I believe the moment has arrived, as you have always understood, to ensure our concentration lands on the results themselves rather than on reasons explaining why we fell short.

Jim Kennedy

analyst
#25

Great, thanks. I have another question about the terpene agreement, or the revised agreement. Suppose demand rises, and say you do white label of product, and you wind up with what we hope is a nice problem — demand a year from now that's far, far greater than it is right now. How does that connect back to the agreement with respect to your lower commitment and the pricing? How should we think about that if demand does go up dramatically?

John Gibson

executive
#26

The most straightforward response is that everything I did was put a ceiling on our take-or-pay, and beyond that, whatever we require, we're able to purchase at market, and we're able to purchase from anyone offering us the best price. So what we did was simply bring an existing obligation down to a level consistent with what we think this year's forecast for our product's demand will be. Our hope is that we're purchasing more again from Florida Chemical. Later in the year — we've built a terrific relationship. I'm extremely grateful to them for collaborating with us to secure this modification, so that it supports our company's success, but we're able to purchase as much as we need.

Jim Kennedy

analyst
#27

Excellent. All right, many thanks.

John Gibson

executive
#28

Seems we've got no more questions, operator.

John Gibson

executive
#29

I appreciate it very much. To everyone who has come on today, I want to express my gratitude. Looking at the folks on this call right now, a large number of them are staff members, and in just a short while we will be holding a company-wide gathering, so it makes me glad to learn that our team members are tuning in and are curious about the direction the business is headed, and we will be speaking with them face to face momentarily. Being here is a genuine pleasure, and I am eager to collaborate closely with the management team and the workforce as we concentrate on creating a thriving business over the long haul at Flotek and reaching that breakeven mark at the earliest opportunity; we are grateful for the backing of every one of our shareholders, and at the close of Q1 we will bring everybody up to date on what we have been doing, and I am hopeful there will be some genuinely positive developments for us to share as well. Many thanks, and I appreciate it.

Operator

operator
#30

That brings today's call to a close. We appreciate your joining us for the presentation. You're welcome to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Flotek Industries, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Flotek Industries, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Flotek Industries, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.